Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Rhythm Biosciences Ltd has achieved its 2024 milestones, including the release of its 2nd Generation ColoSTAT® Beta kits for colorectal cancer detection. The company secured $3.23 million from the R&D Tax Incentive and raised $3.5 million through a share placement, positioning itself for further commercialization efforts. With plans for a commercial launch in late 2025, Rhythm is actively engaging with regulatory bodies and laboratory partners across key markets.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.